US7429647B2ExpiredUtilityPatentIndex 44
Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
Est. expiryJun 24, 2016(expired)· nominal 20-yr term from priority
A61P 7/00A61K 39/395Y10S530/868C07K 16/34Y10S424/80G01N 33/80C07K 2319/00C07K 2317/55Y10S424/81A61K 38/00C07K 14/00C12N 15/62
44
PatentIndex Score
0
Cited by
29
References
9
Claims
Abstract
Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1 a to 16 b . The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
Claims
exact text as granted — not AI-modified1. A purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens of the partial DVI phenotype comprising
a V H region having SEQ ID NO: 58 or SEQ ID NO: 62, and
a V L region.
2. The polypeptide of claim 1 , wherein the polypeptide is an antigen binding Fab fragment.
3. The polypeptide of claim 1 , wherein the polypeptide is an immunoglobulin specific for a Rhesus D antigen.
4. The polypeptide of claim 3 , wherein the immunoglobulin comprises at least one defined isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
5. A recombinant polynucleotide which encodes the polypeptide of claim 1 .
6. A composition comprising at least one polypeptide of claim 1 and a pharmaceutically acceptable carrier.
7. A composition comprising at least one immunoglobulin of claim 3 and a pharmaceutically acceptable carrier.
8. A diagnostic composition for Rhesus D typing comprising at least one polypeptide of claim 1 .
9. A diagnostic composition for Rhesus D typing comprising at least one immunoglobulin of claim 3 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.